What is SelectION?
SelectION Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for autoimmune conditions driven by T cells. Their flagship candidate, si-544, is a first-in-class Kv1.3 blocker designed to selectively neutralize pathogenic T cells while preserving essential immune functions. The company's therapeutic pipeline targets a spectrum of autoimmune disorders, including psoriasis, rheumatoid arthritis, and multiple sclerosis, holding the promise of substantial clinical impact. By focusing on the underlying mechanisms of autoimmunity, SelectION Therapeutics aims to deliver enduring disease modification and enhance patient well-being.
How much funding has SelectION raised?
SelectION has raised a total of $46.4M across 2 funding rounds:
Series A
$41M
Private Equity
$5.4M
Series A (2019): $41M with participation from SDL Ventures and Gloabl Source Ventures
Private Equity (2025): $5.4M, investors not publicly disclosed
Key Investors in SelectION
SDL Ventures
SDL Ventures is an investment firm focused on technology startups, founded by Dr. Donald R. Scifres, who previously established SDL, Inc. The firm partners with Michael L. Foster to identify and back promising technology ventures.
Gloabl Source Ventures
Gloabl Source Ventures is an investment entity participating in the funding round. Further details on their investment focus are not publicly disclosed.
What's next for SelectION?
With this latest round of major enterprise-level funding, SelectION Therapeutics is poised to accelerate its clinical development programs and expand its research initiatives. The strategic investment will likely fuel the advancement of si-544 through further clinical trials and support the exploration of new therapeutic applications. This backing signals strong confidence in the company's scientific approach and its potential to address significant unmet needs in the autoimmune disease landscape, positioning SelectION for substantial growth and market penetration.
See full SelectION company page
